Afficher la notice abrégée

Untreated patients with multiple sclerosis: a study of French expert centers

dc.rights.licenseopenen_US
dc.contributor.authorMOISSET, X.
dc.contributor.authorFOUCHARD, A.-A.
dc.contributor.authorPEREIRA, B.
dc.contributor.authorTAITHE, F.
dc.contributor.authorMATHEY, G.
dc.contributor.authorEDAN, G.
dc.contributor.authorCIRON, J.
hal.structure.identifierNeurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
dc.contributor.authorBROCHET, Bruno
dc.contributor.authorDE SEZE, J.
dc.contributor.authorPAPEIX, C.
dc.contributor.authorVERMERSCH, P.
dc.contributor.authorLABAUGE, P.
dc.contributor.authorDEFER, G.
dc.contributor.authorLEBRUN-FRENAY, C.
dc.contributor.authorMOREAU, T.
dc.contributor.authorLAPLAUD, D.
dc.contributor.authorBERGER, E.
dc.contributor.authorPELLETIER, J.
dc.contributor.authorSTANKOFF, B.
dc.contributor.authorGOUT, O.
dc.contributor.authorTHOUVENOT, E.
dc.contributor.authorHEINZLEF, O.
dc.contributor.authorAL-KHEDR, A.
dc.contributor.authorBOURRE, B.
dc.contributor.authorCASEZ, O.
dc.contributor.authorCABRE, P.
dc.contributor.authorMONTCUQUET, A.
dc.contributor.authorCREEANGE, A.
dc.contributor.authorCAMDESSANCHE, J.-P.
dc.contributor.authorBAKCHINE, S.
dc.contributor.authorMAUROUSSET, A.
dc.contributor.authorHANKIEWICZ, K.
dc.contributor.authorPOTTIER, C.
dc.contributor.authorMAUBEUGE, N.
dc.contributor.authorDIMITRI, Boulos, D.
dc.contributor.authorNIFLE, C.
dc.contributor.authorVUKUSIC, S.
dc.contributor.authorCLAVELOU, P.
dc.date.accessioned2022-03-24T15:02:22Z
dc.date.available2022-03-24T15:02:22Z
dc.date.issued2021-06
dc.identifier.issn1468-1331en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/136525
dc.description.abstractEnBackground and purpose : Disease-modifying therapies (DMTs) have an impact on relapses and disease progression. Nonetheless, many patients with multiple sclerosis (MS) remain untreated. The objectives of the present study were to determine the proportion of untreated patients with MS followed in expert centers in France and to determine the predictive factors of nontreatment. Methods : We conducted a retrospective cohort study. Data were extracted from the 38 centers participating in the European Database for Multiple Sclerosis (EDMUS) on December 15, 2018, and patients with MS seen at least once during the study period (from June 15, 2016 to June 14, 2017) were included. Results : Of the 21,189 patients with MS (age 47.1 ± 13.1 years; Expanded Disability Status Scale (EDSS) score 3.4 ± 2.4), 6,631 (31.3%; 95% confidence interval [CI] 30.7–31.9) were not receiving any DMT. Although patients with a relapsing-remitting course (n = 11,693) were the most likely to receive DMT, 14.8% (95% CI 14.2–15.4) were still untreated (6.8% never treated). After multivariate analysis among patients with relapsing-remitting MS, the main factors explaining never having been treated were: not having ≥9 lesions on brain magnetic resonance imaging (odds ratio [OR] 0.52 [95% CI 0.44–0.61]) and lower EDSS score (OR 0.78 [95% CI 0.74–0.82]). Most patients with progressive MS (50.4% for secondary and 64.2% for primary progressive MS) did not receive any DMT during the study period, while 11.6% of patients with secondary and 34.0% of patients with primary progressive MS had never received any DMT. Conclusion : A significant proportion of patients with MS did not receive any DMT, even though such treatments are reimbursed by the healthcare system for French patients. This result highlights the unmet need for current DMTs for a large subgroup of patients with MS.
dc.description.sponsorshipObservatoire Français de la Sclérose en Plaquesen_US
dc.language.isoENen_US
dc.subject.enMultiple sclerosis
dc.subject.enProgressive
dc.subject.enRelapsing-remitting
dc.subject.enUnmet medical needs
dc.subject.enUntreated
dc.title.enUntreated patients with multiple sclerosis: a study of French expert centers
dc.title.alternativeEur J Neurolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1111/ene.14790en_US
dc.subject.halSciences du Vivant [q-bio]/Neurosciences [q-bio.NC]en_US
dc.identifier.pubmed33650261en_US
bordeaux.journalEuropean Journal of Neurologyen_US
bordeaux.page2026-2036en_US
bordeaux.volume28en_US
bordeaux.hal.laboratoriesNeurocentre Magendie - UMR-S 1215en_US
bordeaux.issue6en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=European%20Journal%20of%20Neurology&rft.date=2021-06&rft.volume=28&rft.issue=6&rft.spage=2026-2036&rft.epage=2026-2036&rft.eissn=1468-1331&rft.issn=1468-1331&rft.au=MOISSET,%20X.&FOUCHARD,%20A.-A.&PEREIRA,%20B.&TAITHE,%20F.&MATHEY,%20G.&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
MAGENDIE_EurJNeurol_2021_Moiss ...
Taille:
1.004Mo
Format:
PDF
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée